POST Online Media Lite Edition



 

Silence Therapeutics CEO Ali Mortazavi on leave of absence

Staff writer |
London, United Kingdom - July 31, 2015, London, United Kingdom - Silence Therapeutics, a developer of RNA therapeutics, announces that its CEO Ali Mortazavi has taken a temporary compassionate leave of absence for approximately two months.




Mr. Mortazavi joined Silence in August 2012 as director of corporate strategy. He has more than 17 years of experience in financial services. He started his career as a Technology Analyst at Duncan Lawrie then Credit Lyonnais Securities.

Mr. Mortazavi co-founded Evolution Securities and ran the principal trading and market making arm. He has extensive experience in small companies and has had significant stakes in UK listed technology and biotech ventures.

The Company's Non-Executive Chairman, Alastair Riddell, will take on the role of Executive Chairman on an interim basis, until Ali Mortazavi's return.

Mr. Riddell joined the Board of Silence in November 2013 and was appointed Non-Executive Chairman in January 2015. He has 32 years of experience in the biopharmaceutical sector, including 15 years as CEO and Chairman of several UK biotechs.

 LATEST MOVES FROM United Kingdom 

John Lewis Of Hungerford appoints Kiran Noonan as acting chair
Ferroglobe appoints Marco Levi as chief executive officer
Tullow Oil appoints Dorothy Thompson as interim chair
Arla Foods says CFO Natalie Knigh to leave
Superdry promotes Julian Dunkerton to full time CEO

What to read next

Silence Therapeutics appoints David Ellam as CFO
Silence Therapeutics appoints new VP of research
Silence Therapeutics appoints head of research & development